Biotech Startups

Anyo Labs develops AI-enabled computational chemistry technology for drug discovery, building on research from the University of Gothenburg. The company serves pharmaceutical and biotech organizations seeking to accelerate the drug development process.

1 investor

AOBiome Therapeutics is a late-stage biotechnology company developing microbiome-based treatments for inflammatory skin conditions such as atopic dermatitis and pruritus. Its lead candidate, B244, uses a single strain of Ammonia Oxidizing Bacteria to moderate immune response by simultaneously down-regulating multiple inflammatory markers (IL-4, IL-5, IL-13, IL-31).

1 investor

Applied BioCode develops multiplex diagnostic testing products for infectious disease detection using proprietary barcoded magnetic bead technology. The company serves clinical and research markets with panels that detect bacterial and fungal pathogens and antimicrobial resistance markers.

1 investor

Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery. The company operates across the Chinese and global healthcare markets, spanning target identification, medicinal chemistry, and clinical development.

1 investor

Aperture Bio develops technologies to translate human tumor biology in order to reduce risk in preclinical drug development.

1 investor

Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging. It targets shared drivers of both familial and sporadic disease, often related to neuroinflammation.

1 investor

Apex Labs is a biotechnology and emerging therapeutics company developing clinical solutions, likely focused on psychedelic-assisted therapies and drug development. The company is led by a team with deep expertise in pharmaceutical development, clinical trials, commercialization, and regulatory affairs.

1 investor

1 investor

Aplantex operates a modular green biotechnology platform that uses proprietary photosynthetic "phytoreplicators" to locally produce plant biomass and extract active plant compounds such as polyphenols with antioxidant, anti-inflammatory, antimicrobial and anti-aging properties. It supplies certified molecules to the food, pharmaceutical, cosmetics, and natural health industries.

1 investor

ApoGlyx develops small-molecule aquaporin-9 inhibitors to treat severe inflammatory and metabolic diseases, including acute pancreatitis and diabetes. The company progresses its lead candidate RG210179 through clinical development and collaborates with academic institutions on drug discovery and validation.

1 investor

A portfolio biopharmaceutical company translating basic medical research breakthroughs from leading universities into novel therapeutic medicines. The company develops a diversified pipeline of drug candidates through partnerships with top research institutions and selective in-licensing of clinical-stage programs.

1 investor

1 investor

Applause Pharma develops therapeutic drugs using rare earth elements as a common platform, leveraging proprietary technologies in reactive oxygen species scavenging, enzyme inhibition, and ion reactions to address unmet medical needs. The company focuses on biotech innovation with scientific evidence-based approaches to treat various diseases.

1 investor

Applied Quantum Materials designs and manufactures silicon, carbon, and germanium nanomaterials and their chemical precursors for advanced technology applications. The company customizes nanomaterial properties for use in batteries, displays, sensing, photovoltaics, and biological imaging.

1 investor

Applied StemCell is a genome engineering platform company that develops proprietary technologies and iPSC expertise to enable safe, scalable integration of large DNA payloads into the mammalian genome for gene and cell-based medicine. The company provides end-to-end solutions for academia and biopharma partners to accelerate therapeutic development.

1 investor

Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.

1 investor

Applied Cells develops cell separation technology, specifically acoustic debris removal and immunomagnetic isolation platforms, to support researchers and clinicians in precision medicine, diagnostic development, and cell therapy advancement.

1 investor

Próspera operates a special economic zone on Roatán, Honduras that offers businesses and residents a streamlined legal and regulatory framework designed to accelerate innovation in biotech, crypto, and other sectors. The zone provides governance infrastructure, competitive taxation, and regulatory flexibility to attract startups and entrepreneurs.

1 investor

Apricity Health develops precision oncology solutions for drug discovery and development. The company was founded by physicians and scientists focused on improving cancer treatment outcomes.

1 investor

Apriligen develops autologous gene therapies for pediatric monogenic diseases, starting with Diamond Blackfan Anemia Syndrome. The company uses lentiviral technology to correct genetic defects by modifying patients' own cells, aiming to provide curative alternatives to traditional transplants.

1 investor

APRINOIA is a clinical-stage biotech company developing diagnostic tools and therapies for neurodegenerative diseases. It focuses on precision medicine in neuroscience to improve diagnosis and treatment of brain disorders for patients.

1 investor

Apriori Bio applies AI/ML combined with biological insights to predict how viruses evolve and to design vaccines, assessing their expected performance before clinical trials. The company operates in the vaccinology and biotech space.

1 investor

APstem develops regenerative medicine therapies based on the activation of dormant pluripotent cells found in adult blood, with an initial focus on treating Type 1 Diabetes and other currently incurable diseases.

1 investor

aptaTargets develops aptamer-based therapeutics and diagnostics for cerebrovascular diseases, with a lead program (ApTOLL) targeting stroke treatment. The company applies aptamer technology platforms to clinical applications in neurology.

1 investor